News & Events

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts

Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections

Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform